University of the West of England Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2015
NCT02216383
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

University of the West of England

Active Ingredients

Drugs in Phase 3 Trials (3)

carbetocin (Pabal) (1 trial)

ergonovine (Ergotrate) (1 trial)

oxytocin (syntocinon) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemorrhage (Phase 3)

Postpartum Hemorrhage (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3